The effect of social deprivation on clinical outcomes and the use of treatments in the UK cystic fibrosis population: a longitudinal study - PubMed (original) (raw)
Comparative Study
The effect of social deprivation on clinical outcomes and the use of treatments in the UK cystic fibrosis population: a longitudinal study
David C Taylor-Robinson et al. Lancet Respir Med. 2013 Apr.
Abstract
Background: Poorer socioeconomic circumstances have been linked with worse outcomes in cystic fibrosis. We assessed whether a relation exists between social deprivation and individual's clinical and health-care outcomes.
Methods: We did a longitudinal registry study of the UK cystic fibrosis population younger than 40 years (8055 people with 49337 observations for weight, the most commonly collected outcome, between Jan 1, 1996, and Dec 31, 2009). We assessed data for weight, height, body-mass index, percent predicted forced expiratory volume in 1 s (%FEV1), risk of Pseudomonas aeruginosa colonisation, and the use of major cystic fibrosis treatment modalities. We used mixed effects models to assess the association between small-area deprivation and clinical and health-care outcomes, adjusting for clinically important covariates. We give continuous outcomes as mean differences, and binary outcomes as odds ratios, comparing extremes of deprivation quintile.
Findings: Compared with the least deprived areas, children from the most deprived areas weighed less (standard deviation [SD] score -0·28, 95% CI -0·38 to -0·18), were shorter (-0·31, -0·40 to -0·21, and had a lower body-mass index (-0·13, -0·22 to -0·04), were more likely to have chronic P aeruginosa infection (odds ratio 1·89, 95% CI 1·34 to 2·66), and have a lower %FEV1 (-4·12 percentage points, 95% CI -5·01 to -3·19). These inequalities were apparent very early in life and did not widen thereafter. On a population level, after adjustment for disease severity, children in the most deprived quintile were more likely to receive intravenous antibiotics (odds ratio 2·52, 95% CI 1·92 to 3·17) and nutritional treatments (1·78, 1·44 to 2·20) compared with individuals in the least deprived quintile. Patients from the most disadvantaged areas were less likely to receive DNase or inhaled antibiotic treatment.
Interpretation: In the UK, children with cystic fibrosis from more disadvantaged areas have worse growth and lung function compared with children from more affluent areas, but these inequalities do not widen with advancing age. Clinicians consider deprivation status, as well as disease status, when making decisions about treatments, and this might mitigate some effects of social disadvantage.
Funding: Medical Research Council (UK).
Copyright © 2013 Elsevier Ltd. All rights reserved.
Figures
Figure 1
Comparison of anthropometric outcomes, by age and socioeconomic status Mean cross-sectional (A) weight, (B) height, and (C) body-mass index (BMI).
Figure 2
Comparison of respiratory outcomes, by age and socioeconomic status Mean cross-sectional (A) FEV1 and (B) Pseudomonas aeruginosa colonisation prevalence.
Figure 3
Comparison of treatment methods, by age and socioeconomic status Proportion of patients who received (A) any intravenous antibiotic treatment, (B) home intravenous antibiotic treatment, (C) hospital intravenous antibiotic treatment, (D) supplemental feeding, (E) DNase, and (F) inhaled antibiotics.
Comment in
- Wealth as a disease modifier in cystic fibrosis.
Schechter MS. Schechter MS. Lancet Respir Med. 2013 Apr;1(2):93-5. doi: 10.1016/S2213-2600(13)70014-6. Epub 2013 Feb 1. Lancet Respir Med. 2013. PMID: 24429076 No abstract available.
Similar articles
- Impact of newborn screening on outcomes and social inequalities in cystic fibrosis: a UK CF registry-based study.
Schlüter DK, Southern KW, Dryden C, Diggle P, Taylor-Robinson D. Schlüter DK, et al. Thorax. 2020 Feb;75(2):123-131. doi: 10.1136/thoraxjnl-2019-213179. Epub 2019 Nov 26. Thorax. 2020. PMID: 31771956 Free PMC article. - Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
Langton Hewer SC, Smyth AR. Langton Hewer SC, et al. Cochrane Database Syst Rev. 2014 Nov 10;(11):CD004197. doi: 10.1002/14651858.CD004197.pub4. Cochrane Database Syst Rev. 2014. PMID: 25383937 Updated. Review. - Prevalence and clinical associations of Staphylococcus aureus small-colony variant respiratory infection in children with cystic fibrosis (SCVSA): a multicentre, observational study.
Wolter DJ, Onchiri FM, Emerson J, Precit MR, Lee M, McNamara S, Nay L, Blackledge M, Uluer A, Orenstein DM, Mann M, Hoover W, Gibson RL, Burns JL, Hoffman LR; SCVSA study group. Wolter DJ, et al. Lancet Respir Med. 2019 Dec;7(12):1027-1038. doi: 10.1016/S2213-2600(19)30365-0. Epub 2019 Nov 11. Lancet Respir Med. 2019. PMID: 31727592 Free PMC article. - Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.
Smith S, Rowbotham NJ, Charbek E. Smith S, et al. Cochrane Database Syst Rev. 2018 Oct 30;10(10):CD008319. doi: 10.1002/14651858.CD008319.pub3. Cochrane Database Syst Rev. 2018. PMID: 30376155 Free PMC article. Updated. - Colistimethate sodium powder and tobramycin powder for inhalation for the treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis: systematic review and economic model.
Tappenden P, Harnan S, Uttley L, Mildred M, Carroll C, Cantrell A. Tappenden P, et al. Health Technol Assess. 2013 Dec;17(56):v-xvii, 1-181. doi: 10.3310/hta17560. Health Technol Assess. 2013. PMID: 24290164 Free PMC article. Review.
Cited by
- Explaining the Sex Effect on Survival in Cystic Fibrosis: a Joint Modeling Study of UK Registry Data.
Taylor-Robinson D, Schlüter DK, Diggle PJ, Barrett JK. Taylor-Robinson D, et al. Epidemiology. 2020 Nov;31(6):872-879. doi: 10.1097/EDE.0000000000001248. Epidemiology. 2020. PMID: 32841985 Free PMC article. - Assessing Differences in Mortality Rates and Risk Factors Between Hispanic and Non-Hispanic Patients With Cystic Fibrosis in California.
Buu MC, Sanders LM, Mayo JA, Milla CE, Wise PH. Buu MC, et al. Chest. 2016 Feb;149(2):380-389. doi: 10.1378/chest.14-2189. Epub 2016 Jan 12. Chest. 2016. PMID: 26086984 Free PMC article. - Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision.
Hoo ZH, Edenborough FP, Curley R, Prtak L, Dewar J, Allenby MI, Nightingale JA, Wildman MJ. Hoo ZH, et al. Eur J Clin Microbiol Infect Dis. 2018 Apr;37(4):735-743. doi: 10.1007/s10096-017-3168-4. Epub 2018 Jan 6. Eur J Clin Microbiol Infect Dis. 2018. PMID: 29307004 Free PMC article. - Low socioeconomic status is associated with worse lung function in the Danish cystic fibrosis population.
Taylor-Robinson DC, Thielen K, Pressler T, Olesen HV, Diderichsen F, Diggle PJ, Smyth R, Whitehead M. Taylor-Robinson DC, et al. Eur Respir J. 2014 Nov;44(5):1363-6. doi: 10.1183/09031936.00063714. Epub 2014 Sep 3. Eur Respir J. 2014. PMID: 25186272 Free PMC article. No abstract available. - Adherence to airway clearance therapy in pediatric cystic fibrosis: Socioeconomic factors and respiratory outcomes.
Oates GR, Stepanikova I, Gamble S, Gutierrez HH, Harris WT. Oates GR, et al. Pediatr Pulmonol. 2015 Dec;50(12):1244-52. doi: 10.1002/ppul.23317. Epub 2015 Oct 5. Pediatr Pulmonol. 2015. PMID: 26436321 Free PMC article.
References
- Cystic Fibrosis Trust UK CF Registry annual data report 2010. http://www.cftrust.org.uk/aboutcf/publications/cfregistryreports/ (accessed Sept 28, 2012).
- Schechter MS, Shelton BJ, Margolis PA, Fitzsimmons SC. The association of socioeconomic status with outcomes in cystic fibrosis patients in the United States. Am J Respir Crit Care Med. 2001;163:1331–1337. - PubMed
- O'Connor GT, Quinton HB, Kneeland T. Median household income and mortality rate in cystic fibrosis. Pediatrics. 2003;111:e333–e339. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials